<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Womens Health</journal-id><journal-id journal-id-type="iso-abbrev">Int J Womens Health</journal-id><journal-id journal-id-type="publisher-id">International Journal of Women's Health</journal-id><journal-title-group><journal-title>International Journal of Women's Health</journal-title></journal-title-group><issn pub-type="epub">1179-1411</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23785247</article-id><article-id pub-id-type="pmc">3682642</article-id><article-id pub-id-type="doi">10.2147/IJWH.S46678</article-id><article-id pub-id-type="publisher-id">ijwh-5-277</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Screening for <italic>Chlamydia trachomatis</italic> infection among infertile women in Saudi Arabia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kamel</surname><given-names>Remah M</given-names></name><xref ref-type="corresp" rid="c1-ijwh-5-277"></xref></contrib><aff id="af1-ijwh-5-277">Department of Obstetrics and Gynecology, Faculty of Medicine, University of Jazan, Saudi Arabia</aff></contrib-group><author-notes><corresp id="c1-ijwh-5-277">Correspondence: Remah M Kamel, 4 Tyndall’s Park Road, Clifton, Bristol, BS8 1PG, United Kingdom, Tel +44 77 8973 8750, Fax +966 7322 0058, Email <email>rkamel@jazanu.edu.sa</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>06</day><month>6</month><year>2013</year></pub-date><volume>5</volume><fpage>277</fpage><lpage>284</lpage><permissions><copyright-statement>© 2013 Kamel, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2013</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="2273" xml_f="2283" txt_i="11" txt_f="21">Background</offsets></title><p><italic><offsets xml_i="2302" xml_f="2323" txt_i="22" txt_f="43">Chlamydia trachomatis</offsets></italic><offsets xml_i="2332" xml_f="2430" txt_i="43" txt_f="141"> infection is a worldwide-distributed sexually transmitted infection that may lead to infertility.</offsets></p></sec><sec><title><offsets xml_i="2452" xml_f="2462" txt_i="143" txt_f="153">Objectives</offsets></title><p><offsets xml_i="2473" xml_f="2517" txt_i="154" txt_f="198">This study aims to report the prevalence of </offsets><italic><offsets xml_i="2525" xml_f="2546" txt_i="198" txt_f="219">Chlamydia trachomatis</offsets></italic><offsets xml_i="2555" xml_f="2604" txt_i="219" txt_f="268"> infection among infertile women in Saudi Arabia.</offsets></p></sec><sec><title><offsets xml_i="2626" xml_f="2646" txt_i="270" txt_f="290">Patients and methods</offsets></title><p><offsets xml_i="2657" xml_f="2668" txt_i="291" txt_f="302">A community</offsets><italic><offsets xml_i="2676" xml_f="2677" txt_i="302" txt_f="303">-</offsets></italic><offsets xml_i="2686" xml_f="3337" txt_i="303" txt_f="954">based study carried out at the obstetrics and gynecology clinic at Jazan General Hospital, Saudi Arabia. The study group included 640 Saudi infertile women who were aged between 18 and 40 years and who attended the gynecology clinic for infertility examination throughout 1 year of study (from July 1, 2011 to June 30, 2012). The randomized control group included 100 Saudi fertile women who attended the obstetrics clinic for routine antenatal care. All recruited women were screened for chlamydia infection by enzyme-linked immunosorbent assay (ELISA) for detection of serum-specific antibodies and then retested by the McCoy cell culture technique.</offsets></p></sec><sec><title><offsets xml_i="3359" xml_f="3366" txt_i="956" txt_f="963">Results</offsets></title><p><offsets xml_i="3377" xml_f="3395" txt_i="964" txt_f="982">The prevalence of </offsets><italic><offsets xml_i="3403" xml_f="3424" txt_i="982" txt_f="1003">Chlamydia trachomatis</offsets></italic><offsets xml_i="3433" xml_f="3588" txt_i="1003" txt_f="1158"> infection among infertile women was high, at 15.0%. The rate of chlamydia infection detected by ELISA was 9.84%, and it was 12.03% by the culture method (</offsets><italic><offsets xml_i="3596" xml_f="3597" txt_i="1158" txt_f="1159">P</offsets></italic><offsets xml_i="3606" xml_f="3617" txt_i="1159" txt_f="1170"> = 0.2443).</offsets></p></sec><sec><title><offsets xml_i="3639" xml_f="3649" txt_i="1172" txt_f="1182">Conclusion</offsets></title><p><offsets xml_i="3660" xml_f="3683" txt_i="1183" txt_f="1206">The high prevalence of </offsets><italic><offsets xml_i="3691" xml_f="3712" txt_i="1206" txt_f="1227">Chlamydia trachomatis</offsets></italic><offsets xml_i="3721" xml_f="3922" txt_i="1227" txt_f="1428"> infection among Saudi infertile women demands a national screening program for early detection among infertile couples. ELISA is available as a simple screening test alternative to the culture method.</offsets></p></sec></abstract><kwd-group><kwd>Chlamydia trachomatis</kwd><kwd>ELISA</kwd><kwd>McCoy cell culture</kwd><kwd>infertility</kwd><kwd>sexually transmitted infection</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="4147" xml_f="4159" txt_i="1437" txt_f="1449">Introduction</offsets></title><p><italic><offsets xml_i="4178" xml_f="4199" txt_i="1450" txt_f="1471">Chlamydia trachomatis</offsets></italic><offsets xml_i="4208" xml_f="4538" txt_i="1471" txt_f="1801"> (serotypes D–K) are obligatory intracellular gram-negative bacteria that primarily infect the female cervix, urethra, and fallopian tubes. The majority of infection is asymptomatic and goes undetected, with an increased risk of pelvic inflammatory disease, and is the leading cause of ectopic pregnancy, tubal factor infertility,</offsets><xref ref-type="bibr" rid="b1-ijwh-5-277"><offsets xml_i="4580" xml_f="4581" txt_i="1801" txt_f="1802">1</offsets></xref><offsets xml_i="4588" xml_f="4589" txt_i="1802" txt_f="1803">–</offsets><xref ref-type="bibr" rid="b3-ijwh-5-277"><offsets xml_i="4631" xml_f="4632" txt_i="1803" txt_f="1804">3</offsets></xref><offsets xml_i="4639" xml_f="4665" txt_i="1804" txt_f="1830"> and chronic pelvic pains.</offsets></p><p><offsets xml_i="4672" xml_f="4974" txt_i="1831" txt_f="2133">In Saudi Arabia, the incidence of sexually transmitted infections is low compared with that in developed countries. Gonococcal and nongonococcal urethritis and genital warts have been reported frequently among Saudis, whereas AIDS, syphilis, and genital herpes are frequently reported among non-Saudis.</offsets><xref ref-type="bibr" rid="b4-ijwh-5-277"><offsets xml_i="5016" xml_f="5017" txt_i="2133" txt_f="2134">4</offsets></xref></p><p><offsets xml_i="5031" xml_f="5643" txt_i="2135" txt_f="2747">For diagnosis of chlamydia infection, cell culture of urogenital specimens has been considered the ideal method, although few laboratories could offer this, due to its cost and lack of experience in the cell culture technique. Accurate results depend on the proper sample taking, carrying, storage, and interpretation. Although culture is 100% specific for chlamydia (no false positives), there is a growing observation that culture is not 100% sensitive. The combination of 100% specificity and the ability to detect viable organisms makes culture the standard for legal applications such as for sexual assault.</offsets></p><p><offsets xml_i="5650" xml_f="6029" txt_i="2748" txt_f="3127">With the availability of more rapid assays during the 1980s, many laboratories started to use enzyme-linked immunosorbent assay (ELISA) due to its lesser demands on cost, skills, and time required for obtaining the results. However, these tests were less sensitive, as detection of antibodies in a single serum sample has frequently been found in the absence of active infection.</offsets><xref ref-type="bibr" rid="b5-ijwh-5-277"><offsets xml_i="6071" xml_f="6072" txt_i="3127" txt_f="3128">5</offsets></xref><offsets xml_i="6079" xml_f="6339" txt_i="3128" txt_f="3388"> Despite the difficulty of differentiating between previous and current infections, the presence of chlamydia-specific antibody (immunoglobulin [Ig]A) is significantly associated with upper genital tract infection, particularly when the antibody titre is high.</offsets><xref ref-type="bibr" rid="b6-ijwh-5-277"><offsets xml_i="6381" xml_f="6382" txt_i="3388" txt_f="3389">6</offsets></xref><offsets xml_i="6389" xml_f="6390" txt_i="3389" txt_f="3390">,</offsets><xref ref-type="bibr" rid="b7-ijwh-5-277"><offsets xml_i="6432" xml_f="6433" txt_i="3390" txt_f="3391">7</offsets></xref><offsets xml_i="6440" xml_f="6596" txt_i="3391" txt_f="3547"> As sensitivity of the ELISA test is low, this can assist but cannot replace direct antigen detection or isolation of the organism by the culture technique.</offsets><xref ref-type="bibr" rid="b8-ijwh-5-277"><offsets xml_i="6638" xml_f="6639" txt_i="3547" txt_f="3548">8</offsets></xref></p><p><offsets xml_i="6653" xml_f="7034" txt_i="3549" txt_f="3930">Another widely used rapid simple test is enzyme immunoassay. It does not require any sophisticated equipment and it takes only 30 minutes to be completed. It is significantly less sensitive and specific than the laboratory-based tests. Reported sensitivities of rapid tests relative to the culture range from 52% to 85% for endocervical swabs, and their specificities are over 95%.</offsets><xref ref-type="bibr" rid="b9-ijwh-5-277"><offsets xml_i="7076" xml_f="7077" txt_i="3930" txt_f="3931">9</offsets></xref><offsets xml_i="7084" xml_f="7085" txt_i="3931" txt_f="3932">–</offsets><xref ref-type="bibr" rid="b11-ijwh-5-277"><offsets xml_i="7128" xml_f="7130" txt_i="3932" txt_f="3934">11</offsets></xref><offsets xml_i="7137" xml_f="7352" txt_i="3934" txt_f="4149"> However, rapid tests are not recommended to be used in a low-prevalence population or for asymptomatic women, due to the potential for false positives. Their results should always be confirmed by a laboratory test.</offsets></p><p><offsets xml_i="7359" xml_f="7594" txt_i="4150" txt_f="4385">More recent and very sensitive nucleic acid amplification techniques (NAATs), such as polymerase chain reaction and ligase chain reaction, have been used for detection of chlamydia genetic material DNA in cervical and urethral samples.</offsets><xref ref-type="bibr" rid="b12-ijwh-5-277"><offsets xml_i="7637" xml_f="7639" txt_i="4385" txt_f="4387">12</offsets></xref></p><p><offsets xml_i="7653" xml_f="8130" txt_i="4388" txt_f="4865">A further development is nucleic acid hybridization (DNA-Probe) tests, which also detect chlamydia genetic material DNA. These tests are very accurate but are not as sensitive as the NAATs. Other diagnostic tests include transcription-mediated amplification, which amplifies the ribosomal-RNA; strand displacement amplification; and direct fluorescent antibody tests. Papanicolaou smear is not an option for chlamydia screening, as it has poor sensitivity and poor specificity.</offsets></p><p><offsets xml_i="8137" xml_f="8211" txt_i="4866" txt_f="4940">Sweden is known to have the best chlamydia screening program in the world.</offsets><xref ref-type="bibr" rid="b13-ijwh-5-277"><offsets xml_i="8254" xml_f="8256" txt_i="4940" txt_f="4942">13</offsets></xref><offsets xml_i="8263" xml_f="8369" txt_i="4942" txt_f="5048"> In the USA, the Centers for Disease Control and Prevention have supported a screening program since 1988.</offsets><xref ref-type="bibr" rid="b14-ijwh-5-277"><offsets xml_i="8412" xml_f="8414" txt_i="5048" txt_f="5050">14</offsets></xref><offsets xml_i="8421" xml_f="8560" txt_i="5050" txt_f="5189"> The phased implementation of a national chlamydia screening program in the UK offers screening for all sexually active women, using NAATs.</offsets><xref ref-type="bibr" rid="b15-ijwh-5-277"><offsets xml_i="8603" xml_f="8605" txt_i="5189" txt_f="5191">15</offsets></xref></p><p><offsets xml_i="8619" xml_f="8726" txt_i="5192" txt_f="5299">Several studies have reported a decline in chlamydia prevalence after early screening and proper treatment.</offsets><xref ref-type="bibr" rid="b16-ijwh-5-277"><offsets xml_i="8769" xml_f="8771" txt_i="5299" txt_f="5301">16</offsets></xref><offsets xml_i="8778" xml_f="8779" txt_i="5301" txt_f="5302">–</offsets><xref ref-type="bibr" rid="b18-ijwh-5-277"><offsets xml_i="8822" xml_f="8824" txt_i="5302" txt_f="5304">18</offsets></xref><offsets xml_i="8831" xml_f="9020" txt_i="5304" txt_f="5493"> The best evidence to date about the effectiveness of screening for chlamydia infection in preventing pelvic inflammatory disease is a randomized controlled trial conducted in Seattle, USA.</offsets><xref ref-type="bibr" rid="b19-ijwh-5-277"><offsets xml_i="9063" xml_f="9065" txt_i="5493" txt_f="5495">19</offsets></xref><offsets xml_i="9072" xml_f="9121" txt_i="5495" txt_f="5544"> Two Swedish studies have supported its findings.</offsets><xref ref-type="bibr" rid="b20-ijwh-5-277"><offsets xml_i="9164" xml_f="9166" txt_i="5544" txt_f="5546">20</offsets></xref><offsets xml_i="9173" xml_f="9174" txt_i="5546" txt_f="5547">,</offsets><xref ref-type="bibr" rid="b21-ijwh-5-277"><offsets xml_i="9217" xml_f="9219" txt_i="5547" txt_f="5549">21</offsets></xref><offsets xml_i="9226" xml_f="9370" txt_i="5549" txt_f="5693"> Selective screening is more cost-effective than universal screening, although the latter may be indicated when prevalence of infection is high.</offsets><xref ref-type="bibr" rid="b22-ijwh-5-277"><offsets xml_i="9413" xml_f="9415" txt_i="5693" txt_f="5695">22</offsets></xref><offsets xml_i="9422" xml_f="9423" txt_i="5695" txt_f="5696">,</offsets><xref ref-type="bibr" rid="b23-ijwh-5-277"><offsets xml_i="9466" xml_f="9468" txt_i="5696" txt_f="5698">23</offsets></xref></p><p><offsets xml_i="9482" xml_f="9623" txt_i="5699" txt_f="5840">The present study aimed to screen Saudi infertile sexually active women in Jazan City, in the southwest region of Saudi Arabia, for possible </offsets><italic><offsets xml_i="9631" xml_f="9652" txt_i="5840" txt_f="5861">Chlamydia trachomatis</offsets></italic><offsets xml_i="9661" xml_f="9672" txt_i="5861" txt_f="5872"> infection.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9713" xml_f="9733" txt_i="5874" txt_f="5894">Patients and methods</offsets></title><p><offsets xml_i="9744" xml_f="9934" txt_i="5895" txt_f="6085">The study was conducted in Jazan General Hospital with the aid of laboratory facilities at the University of Jazan. The study covered a period of 1 year (from July 1, 2011 to June 30, 2012).</offsets></p><p><offsets xml_i="9941" xml_f="10521" txt_i="6086" txt_f="6666">The study group included all Saudi married women of primary and secondary infertility, aged between 18 and 40 years, who attended the outpatient gynecology clinic at Jazan General Hospital for infertility examination during the period of study and agreed to participate (signed informed consent). The randomized control group included 100 Saudi married pregnant women who attended the outpatient obstetrics clinic for routine antenatal care during the period of study and agreed to participate (signed informed consent). Randomization was done using the Random Allocation Software</offsets><sup><offsets xml_i="10526" xml_f="10527" txt_i="6666" txt_f="6667">®</offsets></sup><offsets xml_i="10533" xml_f="10821" txt_i="6667" txt_f="6955"> (developed by Saghaei M, MD, Department of Anesthesia, Isfahan University of Medical Sciences, Iran) (Version 1.0, released on May 2004). Structured meetings were conducted with all recruited women, where they received an information sheet about the study and signed an informed consent.</offsets></p><p><offsets xml_i="10828" xml_f="11344" txt_i="6956" txt_f="7472">Relevant medical records were reviewed for any possible present and past medical or surgical diseases. For a precise detection of chlamydia infection, two methods have been used for screening – an indirect method for detection of chlamydia-specific IgG and IgA antibodies in the sera (ELISA), and a direct method for detection of chlamydia organism (McCoy [Medac Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany] cell culture). All participants’ data and screening results were managed confidentially.</offsets></p><p><offsets xml_i="11351" xml_f="11587" txt_i="7473" txt_f="7709">About 5 mL of venous blood was drawn from each participant for measurement of serum chlamydia IgG and IgA antibodies using a peptide-based enzyme-linked immunosorbent assay (IgG-pELISA Cat No 497/TMB, and IgA-pELISA Cat No 498/TMB Medac</offsets><sup><offsets xml_i="11592" xml_f="11593" txt_i="7709" txt_f="7710">®</offsets></sup><offsets xml_i="11599" xml_f="11617" txt_i="7710" txt_f="7728">, Wedel, Germany).</offsets></p><p><offsets xml_i="11624" xml_f="12320" txt_i="7729" txt_f="8425">Each serum sample had a numerical code so that the clinical condition of the tested woman was unknown to the laboratory technician. All kits used in this study were of the same batch. Each kit contained 96 wells, and all tests were performed before their printed expiry dates. The manufacturer’s instructions for test procedure were followed when performing the assays. The kits, microplates, controls, buffers, diluent, conjugate, 3,3′,5,5′-tetramethylbenzidine substrate, and stop solution were stored at 4°C and allowed to stand for 1 hour at room temperature before use. Results were interpreted according to the manufacturer’s instructions, issuing a negative, equivocal, or positive result.</offsets></p><p><offsets xml_i="12327" xml_f="12713" txt_i="8426" txt_f="8812">The intensity of the color is proportional to the concentration (titer) of the specific antibody in the sample. Cut-off values were calculated according to the manufacturer’s instructions. Samples with optical density values located within the gray zone were retested again after 2 weeks in order to determine a titre change. Results remaining in the gray zone were considered negative.</offsets></p><p><offsets xml_i="12720" xml_f="13382" txt_i="8813" txt_f="9475">The staff nurse of the outpatient clinic and two general practitioners were taught how to collect endocervical and urethral specimens. We used a cyto-brush (which collects more columnar cells than cotton-tipped swabs). The brush was inserted into the cervical os beyond the squamocolumnar junction 1–2 cm deep, rotated, and removed without touching the vaginal mucosa. The urethral swab was inserted 1 cm into the urethra, rotated once prior to removal, and placed in a separate tube of 2-sucrose-phosphate culture-transport medium. The examined women were instructed not to urinate within the previous hour (as urination washes out the infected columnar cells).</offsets></p><p><offsets xml_i="13389" xml_f="13628" txt_i="9476" txt_f="9715">All collected samples were transported on wet ice to the laboratory of the university within 12 hours of collection. Strict adherence to the standard techniques of collecting specimens has biased the findings toward screening outcomes. As </offsets><italic><offsets xml_i="13636" xml_f="13657" txt_i="9715" txt_f="9736">Chlamydia trachomatis</offsets></italic><offsets xml_i="13666" xml_f="13834" txt_i="9736" txt_f="9904"> is an obligatory intracellular pathogen, a specimen that lacks endocervical cells is discarded, as it will greatly increase the probability of a false negative result.</offsets></p><p><offsets xml_i="13841" xml_f="14459" txt_i="9905" txt_f="10523">Specimens were inoculated into coverslip cultures of McCoy cells treated with cycloheximide. The inoculums were centrifuged for 1 hour. We used one-dram shell vials (more sensitive than multiwells). Inoculated cultures were incubated at 37°C for 3 days, washed, fixed in methanol, stained with Giemsa, (Medac Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany) and screened by dark-ground microscopy for possible intracytoplasmic inclusion bodies. Universal precautions were followed when handling such risky specimens, and all our laboratory workers were vaccinated against the hepatitis B virus earlier.</offsets></p><p><offsets xml_i="14466" xml_f="14766" txt_i="10524" txt_f="10824">After the screening reports were collected, all participants were informed about their test results and the implications were discussed with the staff nurse. Any woman with a positive result was referred to the clinic for treatment with a notification letter for her husband to be tested and treated.</offsets></p><p><offsets xml_i="14773" xml_f="14840" txt_i="10825" txt_f="10892">The collected clinical and laboratory data were stored on Microsoft</offsets><sup><offsets xml_i="14845" xml_f="14846" txt_i="10892" txt_f="10893">®</offsets></sup><offsets xml_i="14852" xml_f="14955" txt_i="10893" txt_f="10996"> Excel spreadsheets for Windows and then analyzed by suitable statistical methods using the StatsDirect</offsets><sup><offsets xml_i="14960" xml_f="14961" txt_i="10996" txt_f="10997">®</offsets></sup><offsets xml_i="14967" xml_f="15235" txt_i="10997" txt_f="11265"> Statistical Software (Version 2.7.9, released on July 9, 2012, StatsDirect Ltd, Cheshire, UK). The data were double-checked carefully during the process of collection, transcription, and computer inputting. No missing data were encountered. For testing significance, </offsets><italic><offsets xml_i="15243" xml_f="15244" txt_i="11265" txt_f="11266">t</offsets></italic><offsets xml_i="15253" xml_f="15280" txt_i="11266" txt_f="11293">-test and Yates-corrected χ</offsets><sup><offsets xml_i="15285" xml_f="15286" txt_i="11293" txt_f="11294">2</offsets></sup><offsets xml_i="15292" xml_f="15451" txt_i="11294" txt_f="11453"> test with Fisher exact at a confidence interval (CI) of 95% and a significance level of 5% were used. A finding was considered of statistical significance if </offsets><italic><offsets xml_i="15459" xml_f="15460" txt_i="11453" txt_f="11454">P</offsets></italic><offsets xml_i="15469" xml_f="15486" txt_i="11454" txt_f="11468">-value &lt; 0.05.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="15527" xml_f="15534" txt_i="11470" txt_f="11477">Results</offsets></title><p><offsets xml_i="15545" xml_f="15557" txt_i="11478" txt_f="11490">The rate of </offsets><italic><offsets xml_i="15565" xml_f="15586" txt_i="11490" txt_f="11511">Chlamydia trachomatis</offsets></italic><offsets xml_i="15595" xml_f="15690" txt_i="11511" txt_f="11606"> infection among Saudi infertile women was higher than its rate among the Saudi fertile women (</offsets><xref ref-type="table" rid="t1-ijwh-5-277"><offsets xml_i="15733" xml_f="15740" txt_i="11606" txt_f="11613">Table 1</offsets></xref><offsets xml_i="15747" xml_f="15752" txt_i="11613" txt_f="11618"> and </offsets><xref ref-type="fig" rid="f1-ijwh-5-277"><offsets xml_i="15793" xml_f="15801" txt_i="11618" txt_f="11626">Figure 1</offsets></xref><offsets xml_i="15808" xml_f="15810" txt_i="11626" txt_f="11628">).</offsets></p><p><offsets xml_i="15817" xml_f="16080" txt_i="11629" txt_f="11892">The mean age of Saudi infertile women enrolled in this study as the study group was 26.4 ± 4.8 years. Women aged less than 25 years (276 women) had an infection rate of 7.81%, whereas those aged between 25 and 40 years (364 women) had an infection rate of 7.19% (</offsets><xref ref-type="fig" rid="f2-ijwh-5-277"><offsets xml_i="16121" xml_f="16129" txt_i="11892" txt_f="11900">Figure 2</offsets></xref><offsets xml_i="16136" xml_f="16217" txt_i="11900" txt_f="11981">). This was not of statistical significance (CI 0.97–2.42, odds ratio [OR] 1.53, </offsets><italic><offsets xml_i="16225" xml_f="16226" txt_i="11981" txt_f="11982">P</offsets></italic><offsets xml_i="16235" xml_f="16252" txt_i="11982" txt_f="11999">-value = 0.0581).</offsets></p><p><offsets xml_i="16259" xml_f="16440" txt_i="12000" txt_f="12181">Most of the Saudi infertile women had primary infertility (425 women) with an infection rate of 11.72%, whereas 215 women had secondary infertility with an infection rate of 3.28% (</offsets><xref ref-type="table" rid="t2-ijwh-5-277"><offsets xml_i="16483" xml_f="16490" txt_i="12181" txt_f="12188">Table 2</offsets></xref><offsets xml_i="16497" xml_f="16502" txt_i="12188" txt_f="12193"> and </offsets><xref ref-type="fig" rid="f3-ijwh-5-277"><offsets xml_i="16543" xml_f="16551" txt_i="12193" txt_f="12201">Figure 3</offsets></xref><offsets xml_i="16558" xml_f="16560" txt_i="12201" txt_f="12203">).</offsets></p><p><offsets xml_i="16567" xml_f="16920" txt_i="12204" txt_f="12557">The mean infertility duration for the study group was 3.28 ± 1.73 years. Cases with infertility duration less than 5 years were 498 women with an infection rate of 12.5%, whereas those with infertility duration longer than 5 years were 142 women with an infection rate of 2.5%. This finding was not of statistical significance (CI 0.84–2.86, OR = 1.51, </offsets><italic><offsets xml_i="16928" xml_f="16929" txt_i="12557" txt_f="12558">P</offsets></italic><offsets xml_i="16938" xml_f="16955" txt_i="12558" txt_f="12575">-value = 0.1832).</offsets></p><p><offsets xml_i="16962" xml_f="17317" txt_i="12576" txt_f="12931">Among Saudi infertile women, a past history of sexually transmitted infection was mentioned by 165 women (25.78%), whereas 70 women (10.94%) reported a previous pelvic surgery. A history of a new husband in the preceding year was mentioned by 47 women (7.34%), whereas 23 women (3.59%) reported a past use of an intrauterine contraceptive cupper-T device.</offsets></p><p><offsets xml_i="17324" xml_f="17486" txt_i="12932" txt_f="13094">Most women of the study group were asymptomatic (475 women) with an infection rate of 11.72%, whereas 165 women were symptomatic with an infection rate of 3.28% (</offsets><xref ref-type="fig" rid="f4-ijwh-5-277"><offsets xml_i="17527" xml_f="17535" txt_i="13094" txt_f="13102">Figure 4</offsets></xref><offsets xml_i="17542" xml_f="17620" txt_i="13102" txt_f="13180">). This finding was not of statistical significance (CI 0.75–2.28, OR = 1.29, </offsets><italic><offsets xml_i="17628" xml_f="17629" txt_i="13180" txt_f="13181">P</offsets></italic><offsets xml_i="17638" xml_f="17655" txt_i="13181" txt_f="13198">-value = 0.3777).</offsets></p><p><offsets xml_i="17662" xml_f="18119" txt_i="13199" txt_f="13656">Inquiry revealed a complaint of painful micturition in 115 women (17.97%), vaginal discharges in 98 women (15.31%), pelvic pains in 96 women (15.0%), irregular uterine bleeding in 47 women (7.34%), postcoital bleeding in 27 women (4.22%), and urethral discharge in three women (0.47%). On pelvic examination the signs were muco-purulent cervicitis in 224 women (35.0%), cervical friability in 132 women (20.63%), and hypertrophic cervix in 56 women (8.75%).</offsets></p><p><offsets xml_i="18126" xml_f="18151" txt_i="13657" txt_f="13682">The rate of detection of </offsets><italic><offsets xml_i="18159" xml_f="18180" txt_i="13682" txt_f="13703">Chlamydia trachomatis</offsets></italic><offsets xml_i="18189" xml_f="18305" txt_i="13703" txt_f="13819"> infection among infertile women using the ELISA test was 9.84%, whereas it was 12.03% using the culture technique (</offsets><xref ref-type="table" rid="t3-ijwh-5-277"><offsets xml_i="18348" xml_f="18356" txt_i="13819" txt_f="13827">Tables 3</offsets></xref><offsets xml_i="18363" xml_f="18368" txt_i="13827" txt_f="13832"> and </offsets><xref ref-type="table" rid="t4-ijwh-5-277"><offsets xml_i="18411" xml_f="18412" txt_i="13832" txt_f="13833">4</offsets></xref><offsets xml_i="18419" xml_f="18421" txt_i="13833" txt_f="13835">, </offsets><xref ref-type="fig" rid="f5-ijwh-5-277"><offsets xml_i="18462" xml_f="18470" txt_i="13835" txt_f="13843">Figure 5</offsets></xref><offsets xml_i="18477" xml_f="18556" txt_i="13843" txt_f="13922">). This finding was not of statistical significance (CI 0.55–1.15, OR = 0.798, </offsets><italic><offsets xml_i="18564" xml_f="18565" txt_i="13922" txt_f="13923">P</offsets></italic><offsets xml_i="18574" xml_f="18695" txt_i="13923" txt_f="14044">-value = 0.2443). Lastly, a predictive analysis for the screening tests used in this study was done using the StatsDirect</offsets><sup><offsets xml_i="18700" xml_f="18701" txt_i="14044" txt_f="14045">®</offsets></sup><offsets xml_i="18707" xml_f="18730" txt_i="14045" txt_f="14068"> Statistical Software (</offsets><xref ref-type="table" rid="t5-ijwh-5-277"><offsets xml_i="18773" xml_f="18780" txt_i="14068" txt_f="14075">Table 5</offsets></xref><offsets xml_i="18787" xml_f="18789" txt_i="14075" txt_f="14077">).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="18833" xml_f="18843" txt_i="14079" txt_f="14089">Discussion</offsets></title><p><italic><offsets xml_i="18862" xml_f="18883" txt_i="14090" txt_f="14111">Chlamydia trachomatis</offsets></italic><offsets xml_i="18892" xml_f="19210" txt_i="14111" txt_f="14429"> infection is a worldwide-distributed sexually transmitted infection. Prevalence of infection is difficult to estimate without screening, as most of the cases are asymptomatic. Although 929,462 cases of chlamydia infection were reported in the USA, according to the Centers for Disease Control and Prevention, in 2004,</offsets><xref ref-type="bibr" rid="b14-ijwh-5-277"><offsets xml_i="19253" xml_f="19255" txt_i="14429" txt_f="14431">14</offsets></xref><offsets xml_i="19262" xml_f="19338" txt_i="14431" txt_f="14507"> the actual number of cases is thought to be more than 2.8 million per year.</offsets><xref ref-type="bibr" rid="b24-ijwh-5-277"><offsets xml_i="19381" xml_f="19383" txt_i="14507" txt_f="14509">24</offsets></xref><offsets xml_i="19390" xml_f="19514" txt_i="14509" txt_f="14633"> According to the World Health Organization, new cases of chlamydia infection have been estimated globally to be 92 million.</offsets><xref ref-type="bibr" rid="b25-ijwh-5-277"><offsets xml_i="19557" xml_f="19559" txt_i="14633" txt_f="14635">25</offsets></xref><offsets xml_i="19566" xml_f="19682" txt_i="14635" txt_f="14751"> Both health and economic consequences of infection are serious; thus, prevention and early detection are essential.</offsets></p><p><offsets xml_i="19689" xml_f="19873" txt_i="14752" txt_f="14936">The findings of this study highlight the need for chlamydia screening programs, as the prevalence of infection among Saudi infertile women in Jazan City, Saudi Arabia, is high (15.0%).</offsets></p><p><offsets xml_i="19880" xml_f="19942" txt_i="14937" txt_f="14999">Sociodemographic risk factors for infection include young age,</offsets><xref ref-type="bibr" rid="b26-ijwh-5-277"><offsets xml_i="19985" xml_f="19987" txt_i="14999" txt_f="15001">26</offsets></xref><offsets xml_i="19994" xml_f="19995" txt_i="15001" txt_f="15002">,</offsets><xref ref-type="bibr" rid="b27-ijwh-5-277"><offsets xml_i="20038" xml_f="20040" txt_i="15002" txt_f="15004">27</offsets></xref><offsets xml_i="20047" xml_f="20080" txt_i="15004" txt_f="15037"> an urban setting and low income,</offsets><xref ref-type="bibr" rid="b28-ijwh-5-277"><offsets xml_i="20123" xml_f="20125" txt_i="15037" txt_f="15039">28</offsets></xref><offsets xml_i="20132" xml_f="20164" txt_i="15039" txt_f="15071"> having multiple sexual partners</offsets><xref ref-type="bibr" rid="b29-ijwh-5-277"><offsets xml_i="20207" xml_f="20209" txt_i="15071" txt_f="15073">29</offsets></xref><offsets xml_i="20216" xml_f="20240" txt_i="15073" txt_f="15097"> or an infected partner,</offsets><xref ref-type="bibr" rid="b30-ijwh-5-277"><offsets xml_i="20283" xml_f="20285" txt_i="15097" txt_f="15099">30</offsets></xref><offsets xml_i="20292" xml_f="20305" txt_i="15099" txt_f="15112"> nulliparity,</offsets><xref ref-type="bibr" rid="b31-ijwh-5-277"><offsets xml_i="20348" xml_f="20350" txt_i="15112" txt_f="15114">31</offsets></xref><offsets xml_i="20357" xml_f="20436" txt_i="15114" txt_f="15193"> and irregular use of barrier contraceptives or using oral contraceptive pills.</offsets><xref ref-type="bibr" rid="b32-ijwh-5-277"><offsets xml_i="20479" xml_f="20481" txt_i="15193" txt_f="15195">32</offsets></xref></p><p><offsets xml_i="20495" xml_f="20745" txt_i="15196" txt_f="15446">Due to local cultural and social constraints, our study excluded Saudi women aged less than 18 years. Consequently, direct comparison on chlamydia prevalence cannot be made precisely with western studies that include younger women (aged 15–19 years).</offsets><xref ref-type="bibr" rid="b14-ijwh-5-277"><offsets xml_i="20788" xml_f="20790" txt_i="15446" txt_f="15448">14</offsets></xref><offsets xml_i="20797" xml_f="21057" txt_i="15448" txt_f="15708"> Moreover, unmarried Saudi women were excluded from the present study, as the management of any positive cases would create both legal and social problems. Furthermore, routine inquiries about number of sexual partners is not realistic in an Islamic community.</offsets></p><p><offsets xml_i="21064" xml_f="21412" txt_i="15709" txt_f="16057">In our study, the rate of infection was 7.81% for Saudi infertile women aged 18 to less than 25 years. This rate-age association is largely relating to the higher level of sexual activity among young women, whose squamocolumnar junction of the cervix still presents on ectocervix (cervical ectopy), which provides a large target area for infection.</offsets><xref ref-type="bibr" rid="b33-ijwh-5-277"><offsets xml_i="21455" xml_f="21457" txt_i="16057" txt_f="16059">33</offsets></xref><offsets xml_i="21464" xml_f="21575" txt_i="16059" txt_f="16170"> That is why age is used in many countries as a primary determinant for selective chlamydia screening programs.</offsets><xref ref-type="bibr" rid="b34-ijwh-5-277"><offsets xml_i="21618" xml_f="21620" txt_i="16170" txt_f="16172">34</offsets></xref></p><p><offsets xml_i="21634" xml_f="21742" txt_i="16173" txt_f="16281">The prevalence of chlamydia infection among asymptomatic healthy-looking Saudi women is 8.5% in Riyadh City,</offsets><xref ref-type="bibr" rid="b35-ijwh-5-277"><offsets xml_i="21785" xml_f="21787" txt_i="16281" txt_f="16283">35</offsets></xref><offsets xml_i="21794" xml_f="21855" txt_i="16283" txt_f="16344"> whereas it is 4.0% in our study in Jazan City, Saudi Arabia.</offsets></p><p><offsets xml_i="21862" xml_f="22205" txt_i="16345" txt_f="16688">In this study, positive chlamydia was seen in 75 women out of 425 (17.65%) with primary infertility, and in 21 women out of 215 (9.77%) with secondary infertility. In an Indian study, positive chlamydia was seen in 20 women out of the 74 (27.03%) with primary infertility, and in eleven women out of the 36 (30.56%) with secondary infertility.</offsets><xref ref-type="bibr" rid="b36-ijwh-5-277"><offsets xml_i="22248" xml_f="22250" txt_i="16688" txt_f="16690">36</offsets></xref></p><p><offsets xml_i="22264" xml_f="22574" txt_i="16691" txt_f="17001">Although chlamydia infection is not yet a fully reportable infectious disease in Saudi Arabia, sera from patients who attended our clinic in Jazan was 9.06% positive for IgG antibodies and 5.0% positive for IgA antibodies. In Makkah City, chlamydia IgG antibodies were detected in 8.7% of pregnant Saudi women,</offsets><xref ref-type="bibr" rid="b37-ijwh-5-277"><offsets xml_i="22617" xml_f="22619" txt_i="17001" txt_f="17003">37</offsets></xref><offsets xml_i="22626" xml_f="22691" txt_i="17003" txt_f="17068"> whereas in our study, IgG antibodies were detected in only 4.0%.</offsets></p><p><offsets xml_i="22698" xml_f="22769" txt_i="17069" txt_f="17140">This study is considered the first to screen Saudi infertile women for </offsets><italic><offsets xml_i="22777" xml_f="22798" txt_i="17140" txt_f="17161">Chlamydia trachomatis</offsets></italic><offsets xml_i="22807" xml_f="23052" txt_i="17161" txt_f="17406"> infection as a possible causative factor for their infertility. Lack of chlamydia screening among Saudi women might result from a lack of awareness of the high rate of infection among young asymptomatic women and its serious late complications.</offsets></p><p><offsets xml_i="23059" xml_f="23326" txt_i="17407" txt_f="17674">As there is a high prevalence of chlamydia infection among Saudi infertile women (evident in this study) and a high relationship between chlamydia infection and tubal factor infertility (evident in literature), it is mandatory to screen all Saudi infertile women for </offsets><italic><offsets xml_i="23334" xml_f="23355" txt_i="17674" txt_f="17695">Chlamydia trachomatis</offsets></italic><offsets xml_i="23364" xml_f="23443" txt_i="17695" txt_f="17774"> at the start of their infertility examination prior to any invasive procedure.</offsets></p><p><offsets xml_i="23450" xml_f="23738" txt_i="17775" txt_f="18063">The limitations of data surveyed in this study include its restriction to the geographic boundaries of Jazan City, to the time frame of 1 year, and to a specific target risk group (Saudi infertile women). There are several questions needed for further research, such as the prevalence of </offsets><italic><offsets xml_i="23746" xml_f="23767" txt_i="18063" txt_f="18084">Chlamydia trachomatis</offsets></italic><offsets xml_i="23776" xml_f="23980" txt_i="18084" txt_f="18288"> infection among the general population in Saudi Arabia, the cost-effectiveness of selective versus universal screening programs, and the effect of a screening program in reducing the rate of infertility.</offsets></p></sec><sec><title><offsets xml_i="24002" xml_f="24012" txt_i="18290" txt_f="18300">Conclusion</offsets></title><p><offsets xml_i="24023" xml_f="24041" txt_i="18301" txt_f="18319">The prevalence of </offsets><italic><offsets xml_i="24049" xml_f="24070" txt_i="18319" txt_f="18340">Chlamydia trachomatis</offsets></italic><offsets xml_i="24079" xml_f="24243" txt_i="18340" txt_f="18504"> infection among Saudi infertile women at Jazan City, Saudi Arabia, is high (15.0%). This finding calls for a national screening program for the early detection of </offsets><italic><offsets xml_i="24251" xml_f="24272" txt_i="18504" txt_f="18525">Chlamydia trachomatis</offsets></italic><offsets xml_i="24281" xml_f="24332" txt_i="18525" txt_f="18576"> infection among infertile couples in Saudi Arabia.</offsets></p><p><offsets xml_i="24339" xml_f="24592" txt_i="18577" txt_f="18830">The ELISA test seems to be a good alternative to the culture method for screening purposes. It is simple and relatively cheap compared with the McCoy cell culture technique. It has a high specificity (100%) and a high negative predictive value (94.28%).</offsets></p></sec></body><back><fn-group><fn id="fn1-ijwh-5-277"><p><bold>Disclosure</bold></p><p>I hereby declare that this work was carried out in accordance with the requirements of the University of Jazan Regulations and Code of Ethics for Research Programs. It was approved by the Research Review Board. Except where indicated by specific reference in the text, this work is my own work. There was no contribution of any other authors. Any views expressed in the study are those of the author. The work was self-funded. In addition, I state that I have no competing interests.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ijwh-5-277"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehanna</surname><given-names>MT</given-names></name><name><surname>Rizk</surname><given-names>MA</given-names></name><name><surname>Eweiss</surname><given-names>NY</given-names></name><name><surname>Ramadan</surname><given-names>M</given-names></name><name><surname>Zaki</surname><given-names>SA</given-names></name><name><surname>Sadek</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Chlamydial serology among patients with tubal factor infertility and ectopic pregnancy in Alexandria, Egypt</article-title><source>J Sex Transm Dis</source><year>1995</year><volume>22</volume><issue>5</issue><fpage>317</fpage><lpage>321</lpage></element-citation></ref><ref id="b2-ijwh-5-277"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajkhowa</surname><given-names>M</given-names></name><name><surname>Glass</surname><given-names>MR</given-names></name><name><surname>Rutherford</surname><given-names>AJ</given-names></name><name><surname>Balen</surname><given-names>AH</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Cuckle</surname><given-names>HS</given-names></name></person-group><article-title>Trends in the incidence of ectopic pregnancy in England and Wales from 1966 to 1996</article-title><source>BJOG</source><year>2000</year><volume>107</volume><fpage>369</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">10740334</pub-id></element-citation></ref><ref id="b3-ijwh-5-277"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akande</surname><given-names>VA</given-names></name><name><surname>Hunt</surname><given-names>LP</given-names></name><name><surname>Cahill</surname><given-names>DJ</given-names></name><name><surname>Caul</surname><given-names>EO</given-names></name><name><surname>Ford</surname><given-names>WC</given-names></name><name><surname>Jenkins</surname><given-names>JM</given-names></name></person-group><article-title>Tubal damage in infertile women: prediction using chlamydia serology</article-title><source>Hum Reprod</source><year>2003</year><volume>18</volume><issue>9</issue><fpage>1841</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">12923136</pub-id></element-citation></ref><ref id="b4-ijwh-5-277"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madani</surname><given-names>TA</given-names></name></person-group><article-title>Sexually-transmitted infections in Saudi Arabia</article-title><source>J Infectious Dis</source><year>2006</year><volume>10;6</volume><fpage>3</fpage></element-citation></ref><ref id="b5-ijwh-5-277"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Templeton</surname><given-names>A</given-names></name><name><surname>Russell</surname><given-names>I</given-names></name><name><surname>Paavonen</surname><given-names>J</given-names></name><name><surname>Mardh</surname><given-names>P-A</given-names></name><name><surname>Stary</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The accuracy and efficacy of screening tests for chlamydia trachomatis: a systematic review</article-title><source>J Med Microbiol</source><year>2002</year><volume>51</volume><issue>11</issue><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">12466399</pub-id></element-citation></ref><ref id="b6-ijwh-5-277"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DE</given-names></name><name><surname>Spadoni</surname><given-names>LR</given-names></name><name><surname>Foy</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>SP</given-names></name><name><surname>Daling</surname><given-names>JR</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><etal></etal></person-group><article-title>Increased frequency of serum antibodies to chlamydia trachomatis in infertility due to distal tubal disease</article-title><source>Lancet</source><year>1982</year><volume>11</volume><fpage>574</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">6125729</pub-id></element-citation></ref><ref id="b7-ijwh-5-277"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiddelers</surname><given-names>AA</given-names></name><name><surname>Land</surname><given-names>JA</given-names></name><name><surname>Voss</surname><given-names>G</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Severens</surname><given-names>JL</given-names></name></person-group><article-title>Cost-effectiveness of chlamydia antibody tests in subfertile women</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><issue>2</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">15539437</pub-id></element-citation></ref><ref id="b8-ijwh-5-277"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernesky</surname><given-names>M</given-names></name><name><surname>Luinstra</surname><given-names>K</given-names></name><name><surname>Sellors</surname><given-names>J</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Moncada</surname><given-names>J</given-names></name><name><surname>Caul</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Can serology diagnose upper genital tract chlamydia trachomatis infection? Studies on women with pelvic pain, with or without chlamydial plasmid DNA in endometrial biopsy tissue</article-title><source>Sex Transm Dis</source><year>1998</year><volume>25</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9437779</pub-id></element-citation></ref><ref id="b9-ijwh-5-277"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>JH</given-names></name><name><surname>Rivlin</surname><given-names>ME</given-names></name><name><surname>Morrison</surname><given-names>JC</given-names></name></person-group><article-title>Diagnosis of chlamydial infection in pregnant women using the Testpack Chlamydia diagnostic kit</article-title><source>J Obstet Gynecol</source><year>1991</year><volume>77</volume><fpage>801</fpage><lpage>803</lpage></element-citation></ref><ref id="b10-ijwh-5-277"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>DG</given-names></name><name><surname>Martin</surname><given-names>WH</given-names></name></person-group><article-title>A comparison of three rapid chlamydial tests in pregnant and non-pregnant women</article-title><source>J Fam Pract</source><year>1992</year><volume>34</volume><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">1578210</pub-id></element-citation></ref><ref id="b11-ijwh-5-277"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanding</surname><given-names>J</given-names></name><name><surname>Hirsch</surname><given-names>L</given-names></name><name><surname>Stranton</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Aarnaes</surname><given-names>S</given-names></name><name><surname>de la Maza</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Comparison of the Clearview Chlamydia, the PACE 2 assay, and culture for detection of chlamydia trachomatis from cervical specimens in a low-prevalence population</article-title><source>J Clin Microbial</source><year>1993</year><volume>31</volume><fpage>1622</fpage><lpage>1625</lpage></element-citation></ref><ref id="b12-ijwh-5-277"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>McCormack</surname><given-names>WM</given-names></name><name><surname>Chernesky</surname><given-names>MA</given-names></name><name><surname>Martin</surname><given-names>DH</given-names></name><name><surname>Van Der Pol</surname><given-names>B</given-names></name><name><surname>Rice</surname><given-names>PA</given-names></name><etal></etal></person-group><article-title>Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with chlamydia trachomatis</article-title><source>J Clin Microbial</source><year>2003</year><volume>41</volume><issue>8</issue><fpage>3784</fpage><lpage>3789</lpage></element-citation></ref><ref id="b13-ijwh-5-277"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Gertig</surname><given-names>DM</given-names></name><name><surname>McInnes</surname><given-names>JA</given-names></name></person-group><article-title>Genital chlamydia trachomatis infection in Australia</article-title><source>Med J Australia</source><year>1993</year><volume>159</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">8123085</pub-id></element-citation></ref><ref id="b14-ijwh-5-277"><label>14</label><element-citation publication-type="book"><collab>Centers for Disease Control and Prevention (CDCP)</collab><source>Sexually transmitted disease surveillance 2004 supplement, Chlamydia Prevalence Monitoring Project</source><year>2005</year><publisher-loc>Atlanta, US</publisher-loc><publisher-name>Department of Health and Human Services</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/std/chlamydia2004/">http://www.cdc.gov/std/chlamydia2004/</ext-link></comment></element-citation></ref><ref id="b15-ijwh-5-277"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Montagne</surname><given-names>DS</given-names></name><name><surname>Fenton</surname><given-names>KA</given-names></name><name><surname>Randall</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>P</given-names></name></person-group><collab>on behalf of the National Chlamydia Screening Steering Group</collab><article-title>Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening</article-title><source>J Sex Transm Infect</source><year>2004</year><volume>80</volume><issue>8</issue><fpage>335</fpage><lpage>341</lpage></element-citation></ref><ref id="b16-ijwh-5-277"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addiss</surname><given-names>DG</given-names></name><name><surname>Vaughn</surname><given-names>ML</given-names></name><name><surname>Ludka</surname><given-names>D</given-names></name><name><surname>Pfister</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>JP</given-names></name></person-group><article-title>Decreased prevalence of chlamydia trachomatis infection associated with a selective screening program in family planning clinics in Wisconsin</article-title><source>Sex Transm Dis</source><year>1993</year><volume>20</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">8430355</pub-id></element-citation></ref><ref id="b17-ijwh-5-277"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>B</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name></person-group><article-title>Genital chlamydia trachomatis infections in Uppsala County, Sweden, 1985–1993: declining rates for how-much longer?</article-title><source>J Sex Transm Dis</source><year>1995</year><volume>22</volume><fpage>253</fpage><lpage>260</lpage></element-citation></ref><ref id="b18-ijwh-5-277"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>BP</given-names></name><name><surname>Blythe</surname><given-names>MJ</given-names></name><name><surname>Van der Pol</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name></person-group><article-title>Declining prevalence of chlamydial infection among adolescent girls</article-title><source>J Sex Transm Dis</source><year>1996</year><volume>23</volume><fpage>226</fpage><lpage>229</lpage></element-citation></ref><ref id="b19-ijwh-5-277"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholes</surname><given-names>D</given-names></name><name><surname>Stergachis</surname><given-names>A</given-names></name><name><surname>Heidrich</surname><given-names>FE</given-names></name><name><surname>Andrilla</surname><given-names>H</given-names></name><name><surname>Holmes</surname><given-names>KK</given-names></name><name><surname>Stamm</surname><given-names>WE</given-names></name></person-group><article-title>Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>1362</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">8614421</pub-id></element-citation></ref><ref id="b20-ijwh-5-277"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamwendo</surname><given-names>F</given-names></name><name><surname>Forslin</surname><given-names>L</given-names></name><name><surname>Bodin</surname><given-names>L</given-names></name><name><surname>Danielsson</surname><given-names>D</given-names></name></person-group><article-title>Decreasing incidences of gonorrhea and chlamydia associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden</article-title><source>J Sex Transm Dis</source><year>1996</year><volume>23</volume><fpage>384</fpage><lpage>391</lpage></element-citation></ref><ref id="b21-ijwh-5-277"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Low</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Lindblom</surname><given-names>B</given-names></name><name><surname>Herrmann</surname><given-names>B</given-names></name></person-group><article-title>Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>1776</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">9624063</pub-id></element-citation></ref><ref id="b22-ijwh-5-277"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellors</surname><given-names>JW</given-names></name><name><surname>Pickard</surname><given-names>L</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Mahony</surname><given-names>JB</given-names></name><etal></etal></person-group><article-title>Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women</article-title><source>Arch Intern Med</source><year>1992</year><volume>152</volume><fpage>1837</fpage><lpage>1844</lpage><pub-id pub-id-type="pmid">1520050</pub-id></element-citation></ref><ref id="b23-ijwh-5-277"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrazzo</surname><given-names>JM</given-names></name><name><surname>Celum</surname><given-names>CL</given-names></name><name><surname>Hillis</surname><given-names>SD</given-names></name><name><surname>Fine</surname><given-names>D</given-names></name><name><surname>DeLisle</surname><given-names>S</given-names></name><name><surname>Handsfield</surname><given-names>HH</given-names></name></person-group><article-title>Performance and cost-effectiveness of selective screening criteria for chlamydia trachomatis infection in women. Implications for a national chlamydia control strategy</article-title><source>J Sex Transm Dis</source><year>1997</year><volume>24</volume><fpage>131</fpage><lpage>141</lpage></element-citation></ref><ref id="b24-ijwh-5-277"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>H</given-names></name><name><surname>Berman</surname><given-names>S</given-names></name><name><surname>Cates</surname><given-names>W</given-names></name></person-group><article-title>Sexually-transmitted diseases among American youth: incidence and prevalence estimates, 2000</article-title><source>Perspect Sex Reprod Health</source><year>2004</year><volume>36</volume><issue>1</issue><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14982671</pub-id></element-citation></ref><ref id="b25-ijwh-5-277"><label>25</label><element-citation publication-type="webpage"><collab>World Health Organization</collab><source>Global prevalence and incidence of selected curable sexually transmitted infections: overviews and estimates</source><year>2001</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf">http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf</ext-link></comment></element-citation></ref><ref id="b26-ijwh-5-277"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macmillan</surname><given-names>S</given-names></name><name><surname>McKenzie</surname><given-names>H</given-names></name><name><surname>Flett</surname><given-names>G</given-names></name><name><surname>Templeton</surname><given-names>A</given-names></name></person-group><article-title>Which women should be tested for chlamydia trachomatis?</article-title><source>BJOG</source><year>2000</year><volume>107</volume><issue>9</issue><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">11002950</pub-id></element-citation></ref><ref id="b27-ijwh-5-277"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>JM</given-names></name></person-group><article-title>Chlamydia screening in primary care: is it useful, affordable and universal?</article-title><source>J Curr Opin Infect Dis</source><year>2002</year><volume>15</volume><fpage>31</fpage><lpage>36</lpage></element-citation></ref><ref id="b28-ijwh-5-277"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname><given-names>RA</given-names></name><name><surname>Hillis</surname><given-names>SD</given-names></name><name><surname>Shirey</surname><given-names>P</given-names></name><name><surname>Waterman</surname><given-names>SH</given-names></name><name><surname>Greenspan</surname><given-names>JR</given-names></name></person-group><article-title>Chlamydia trachomatis infection among Hispanic women in the California-Mexico border area, 1993: establishing screening criteria in a primary care setting</article-title><source>J Sex Transm Dis</source><year>1995</year><volume>22</volume><fpage>329</fpage><lpage>334</lpage></element-citation></ref><ref id="b29-ijwh-5-277"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosure</surname><given-names>DJ</given-names></name><name><surname>Berman</surname><given-names>S</given-names></name><name><surname>Kleinbaum</surname><given-names>D</given-names></name><name><surname>Halloran</surname><given-names>ME</given-names></name></person-group><article-title>Predictors of chlamydia trachomatis infection among female adolescents: a longitudinal analysis</article-title><source>Am J Epidemiol</source><year>1996</year><volume>144</volume><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">8916511</pub-id></element-citation></ref><ref id="b30-ijwh-5-277"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rietmeijer</surname><given-names>CA</given-names></name><name><surname>Van Bemmelen</surname><given-names>R</given-names></name><name><surname>Judson</surname><given-names>FN</given-names></name><name><surname>Douglas</surname><given-names>JM</given-names><suffix>Jr</suffix></name></person-group><article-title>Incidence and repeat infection rates of chlamydia trachomatis among male and female patients in an STD clinic: implications for screening and re-screening</article-title><source>J Sex Transm Dis</source><year>2002</year><volume>29</volume><issue>2</issue><fpage>65</fpage><lpage>72</lpage></element-citation></ref><ref id="b31-ijwh-5-277"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>RL</given-names></name><name><surname>St George</surname><given-names>K</given-names></name><name><surname>Lassak</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Anhalt</surname><given-names>JP</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names></name></person-group><article-title>Screening for chlamydia trachomatis infection in college women with a polymerase chain reaction assay</article-title><source>J Clin Infect Dis</source><year>1999</year><volume>28</volume><fpage>1002</fpage><lpage>1007</lpage></element-citation></ref><ref id="b32-ijwh-5-277"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottingham</surname><given-names>J</given-names></name><name><surname>Hunter</surname><given-names>D</given-names></name></person-group><article-title>Chlamydia trachomatis and oral contraceptive use: a quantitative review</article-title><source>J Genito-urinary Med</source><year>1992</year><volume>68</volume><fpage>209</fpage><lpage>216</lpage></element-citation></ref><ref id="b33-ijwh-5-277"><label>33</label><element-citation publication-type="book"><collab>Centers for Disease Control and Prevention (CDCP)</collab><source>Sexually transmitted disease surveillance 2003 supplement, Chlamydia Prevalence Monitoring Project</source><year>2004</year><publisher-loc>Atlanta, US</publisher-loc><publisher-name>Department of Health and Human Services</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/std/chlamydia2003/chlamydia2003.pdf">http://www.cdc.gov/std/chlamydia2003/chlamydia2003.pdf</ext-link></comment></element-citation></ref><ref id="b34-ijwh-5-277"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WC</given-names></name><name><surname>Hoffman</surname><given-names>IF</given-names></name><name><surname>Owen-O’Dowd</surname><given-names>J</given-names></name><name><surname>McPherson</surname><given-names>JT</given-names></name><name><surname>Privette</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>JL</given-names></name><etal></etal></person-group><article-title>Selective screening for chlamydial infection: which criteria to use?</article-title><source>Am J Prev Med</source><year>2000</year><volume>18</volume><issue>2</issue><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">10698241</pub-id></element-citation></ref><ref id="b35-ijwh-5-277"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakir</surname><given-names>TM</given-names></name><name><surname>Hossain</surname><given-names>A</given-names></name><name><surname>De-Silva</surname><given-names>S</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Sengupta</surname><given-names>BS</given-names></name><name><surname>El-Sheikh</surname><given-names>MM</given-names></name><etal></etal></person-group><article-title>Enzyme immunoassay diagnosis of chlamydia trachomatis infections in diverse patient groups</article-title><source>J Hyg Epidemiol Microbial Immunol</source><year>1989</year><volume>33</volume><issue>2</issue><fpage>189</fpage><lpage>197</lpage></element-citation></ref><ref id="b36-ijwh-5-277"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Hakim</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>I</given-names></name><name><surname>Rizvi</surname><given-names>M</given-names></name></person-group><article-title>2006. Chlamydia trachomatis infection and female infertility</article-title><source>Indian J Med Res</source><year>2006</year><volume>123</volume><issue>6</issue><fpage>770</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">16885598</pub-id></element-citation></ref><ref id="b37-ijwh-5-277"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghazi</surname><given-names>HO</given-names></name><name><surname>Daghestani</surname><given-names>MH</given-names></name><name><surname>Mohamed</surname><given-names>MF</given-names></name></person-group><article-title>Seropositivity of chlamydia trachomatis mong Saudi pregnant women in Makkah</article-title><source>J Family and Comm Med</source><year>2006</year><volume>13</volume><issue>2</issue><fpage>61</fpage><lpage>64</lpage></element-citation></ref></ref-list></back><floats-group><fig id="f1-ijwh-5-277" position="float"><label>Figure 1</label><caption><p>Prevalence of <italic>Chlamydia trachomatis</italic> infection among Saudi women (cases versus controls).</p></caption><graphic xlink:href="ijwh-5-277f1"></graphic></fig><fig id="f2-ijwh-5-277" position="float"><label>Figure 2</label><caption><p>Histogram with distribution curve according to the age of infected Saudi infertile women (positively skewed to the right: ie, more cases at a young age).</p></caption><graphic xlink:href="ijwh-5-277f2"></graphic></fig><fig id="f3-ijwh-5-277" position="float"><label>Figure 3</label><caption><p><italic>Chlamydia trachomatis</italic> infection among Saudi infertile women (primary versus secondary).</p></caption><graphic xlink:href="ijwh-5-277f3"></graphic></fig><fig id="f4-ijwh-5-277" position="float"><label>Figure 4</label><caption><p><italic>Chlamydia trachomatis</italic> infection among Saudi infertile women (symptomatic versus asymptomatic).</p></caption><graphic xlink:href="ijwh-5-277f4"></graphic></fig><fig id="f5-ijwh-5-277" position="float"><label>Figure 5</label><caption><p>Results of screening tests (Cat.No. 497/TMB and Cat.No. 498/TMB, Medac Gesellschaft für klinische Spezialpräparate mbHGeschäftseinheit Diagnostik, Wedel, Germany) (enzyme-linked immunosorbent assay versus McCoy culture).</p></caption><graphic xlink:href="ijwh-5-277f5"></graphic></fig><table-wrap id="t1-ijwh-5-277" position="float"><label>Table 1</label><caption><p>Prevalence of <italic>Chlamydia trachomatis</italic> infection among Saudi women (cases versus controls)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="3" colspan="1">Screening results</th><th align="left" valign="top" rowspan="3" colspan="1">Cases (infertile women)<break></break>n = 640</th><th align="left" valign="top" rowspan="3" colspan="1">Controls (fertile women)<break></break>n = 100</th><th colspan="2" align="left" valign="top" rowspan="1">Fisher exact 95% CI</th><th align="left" valign="top" rowspan="3" colspan="1"><italic>P</italic>-value</th><th align="left" valign="top" rowspan="3" colspan="1">OR</th></tr><tr><th colspan="2" align="left" valign="top" rowspan="1">
<hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Infected</td><td align="left" valign="top" rowspan="1" colspan="1">96 (15.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (4.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.54</td><td align="left" valign="top" rowspan="1" colspan="1">16.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.0015</td><td align="left" valign="top" rowspan="1" colspan="1">4.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not infected</td><td align="left" valign="top" rowspan="1" colspan="1">544 (85.0%)</td><td align="left" valign="top" rowspan="1" colspan="1">96 (96.0%)</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ijwh-5-277"><p><bold>Abbreviations:</bold> CI, confidence interval; n, number of women; OR, odds ratio; <italic>P</italic>, significance level.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ijwh-5-277" position="float"><label>Table 2</label><caption><p>Prevalence of <italic>Chlamydia trachomatis</italic> infection among Saudi infertile women (primary versus secondary infertility)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="3" colspan="1">Screening results</th><th colspan="2" align="left" valign="top" rowspan="1">Infertile cases (study group)</th><th colspan="2" align="left" valign="top" rowspan="1">Fisher exact 95% CI</th><th align="left" valign="top" rowspan="3" colspan="1"><italic>P</italic>-value</th><th align="left" valign="top" rowspan="3" colspan="1">OR</th></tr><tr><th colspan="2" align="left" valign="top" rowspan="1">
<hr></hr></th><th colspan="2" align="left" valign="top" rowspan="1">
<hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Primary<break></break>n = 425</th><th align="left" valign="top" rowspan="1" colspan="1">Secondary<break></break>n = 215</th><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Infected</td><td align="left" valign="top" rowspan="1" colspan="1">75 (11.72%)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (3.28%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.16</td><td align="left" valign="top" rowspan="1" colspan="1">3.49</td><td align="left" valign="top" rowspan="1" colspan="1">0.0096</td><td align="left" valign="top" rowspan="1" colspan="1">1.98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not infected</td><td align="left" valign="top" rowspan="1" colspan="1">350 (54.69%)</td><td align="left" valign="top" rowspan="1" colspan="1">194 (30.31%)</td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td><td align="left" valign="top" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ijwh-5-277"><p><bold>Abbreviations:</bold> CI, confidence interval; n, number of women; OR, odds ratio; <italic>P</italic>, significance level.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ijwh-5-277" position="float"><label>Table 3</label><caption><p>Interpretation of enzyme-linked immunosorbent assay test results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">IgG</th><th align="left" valign="top" rowspan="1" colspan="1">IgA</th><th align="left" valign="top" rowspan="1" colspan="1">Test interpretation</th><th align="left" valign="top" rowspan="1" colspan="1">No of cases</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">Positive <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">Past <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">Early <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">Possible early <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">Possible past <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">Past with possible early <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">?</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">Early with possible past <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">−</td><td align="left" valign="top" rowspan="1" colspan="1">Negative <italic>Chlamydia trachomatis</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">577</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ijwh-5-277"><p><bold>Abbreviations:</bold> Ig, immunoglobulin; +, positive; −, negative; ?, equivocal.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ijwh-5-277" position="float"><label>Table 4</label><caption><p>Comparing results of screening tests (Cat.No. 497/TMB and Cat.No. 498/TMB, Medac Gesellschaft für klinische Spezialpräparate mbH Geschäftseinheit Diagnostik, Wedel, Germany) (ELISA versus culture)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Screening test</th><th align="left" valign="top" rowspan="1" colspan="1">Positive</th><th align="left" valign="top" rowspan="1" colspan="1">Equivocal</th><th align="left" valign="top" rowspan="1" colspan="1">Negative</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">IgG p-ELISA</td><td align="left" valign="top" rowspan="1" colspan="1">51</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">580</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgA p-ELISA</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">603</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">McCoy cell culture</td><td align="left" valign="top" rowspan="1" colspan="1">77</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">563</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ijwh-5-277"><p><bold>Abbreviations:</bold> ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-ijwh-5-277" position="float"><label>Table 5</label><caption><p>Prediction analysis of screening tests (Cat.No. 497/TMB and Cat.No. 498/TMB, Medac Gesellschaft für klinische Spezialpräparate mbHGeschäftseinheit Diagnostik, Wedel, Germany) (ELISA versus culture)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th align="left" valign="top" rowspan="1" colspan="1">ELISA</th><th align="left" valign="top" rowspan="1" colspan="1">McCoy cell culture</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sensitivity</td><td align="left" valign="top" rowspan="1" colspan="1">65.62%</td><td align="left" valign="top" rowspan="1" colspan="1">80.21%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Specificity</td><td align="left" valign="top" rowspan="1" colspan="1">100.0%</td><td align="left" valign="top" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PPV</td><td align="left" valign="top" rowspan="1" colspan="1">100.0%</td><td align="left" valign="top" rowspan="1" colspan="1">100.0%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NPV</td><td align="left" valign="top" rowspan="1" colspan="1">94.28%</td><td align="left" valign="top" rowspan="1" colspan="1">96.63%</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ijwh-5-277"><p><bold>Abbreviations:</bold> ELISA, enzyme-linked immunosorbent assay; NPV, negative predictive value; PPV, positive predictive value.</p></fn></table-wrap-foot></table-wrap></floats-group></article>